Anthony Altig replaces Thomas Rowland on Ventrus board
This article was originally published in Scrip
Anthony Altig has joined the board of Ventrus Biosciences, a company developing late-stage drugs for gastrointestinal disorders. Mr Altig is CFO of Biotix Holdings, and previously served as CFO of Diversa Corporation. Upon Mr Altig's appointment, Thomas Rowland, former CEO of Ventrus and its current CBO, resigned as a director.